Novel therapies
for infectious disease  

Novexel is an emerging specialty pharmaceutical company focused on the discovery and development of cutting edge antibiotics designed to overcome the increasing global problem of microbial resistance. The Company’s goal is to become Europe’s leading specialty pharmaceutical company in the anti-infectives space.

At present Novexel’s most advanced products are in Phase II clinical development and it has a number of additional novel pre-clinical programmes. The Company’s success to-date is based both on its inherited assets, which are the product of many years of significant investment by sanofi-aventis, and its own core expertise in biology, chemistry, pharmacology, microbiology, and clinical development.

Novexel is headquartered in Paris, France and has a team of 50 people, a vast majority of whom are scientists with an extensive background in anti-infective research and development. The Company is led by a management team with an international track record of success in the biotech and pharma sector.